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Background
Toll like receptors play an important role in fine-tuning
innate immune responses, but genetic variations in TLR
genes have been shown previously to augment immune
responses and susceptibility to autoimmune disease.
Aim
To investigate whether polymorphisms in toll like receptor
(TLR) genes, previously reported to be associated with
immune mediated diseases are implicated in systemic
sclerosis (SSc).
Methods
We genotyped 14 polymorphisms in the TLR 2, 4, 7, 8 and
9 genes in a discovery cohort comprising 452 SSc patients
and 537 controls and a replication cohort consisting of
1170 SSc patients and 925 controls. Furthermore we ana-
lyzed 15 year follow-up data from 964 patients to assess
the potential association of TLR variants with the develop-
ment of disease complications. Next to this, we analyzed
the functional impact of the associated polymorphism on
monocyte derived and myeloid dendritic cells.
Results
Exploiting the discovery cohort, we observed that a rare
functional polymorphism in TLR2 (Pro631His), was asso-
ciated with anti-topoisomerase positivity (p=0.003 OR
2.24 95%CI:1.24-4.04). This observation was validated in
the replication cohort (p=0.0001 OR 2.73 95%CI:1.85-
4.04). In addition, the replication cohort also revealed an
association between the TLR2 variant with the diffuse
subform of the disease and the development of pulmon-
ary arterial hypertension, respectively (p=0.02, Log-Rank
p=0.003, Cox proportional hazards ratio: 5.61 ((95%CI
1.53-20.58)). Functional analysis revealed that monocyte
derived dendritic cells carrying the Pro63His variant pro-
duce more inflammatory mediators (TNFalpha and IL-6)
upon TLR2 mediated stimulation (both p<0.0001).
Conclusion
The rare TLR2Pro631His variant is robustly associated
with anti-topoisomerase positivity, diffuse SSc and the
development of PAH. Besides, this variant influences
TLR2 mediated cell responses. Further research is neces-
sary to reveal the precise role of TLR2 in the disease
pathogenesis of SSc.
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